Nutex Health Inc (NUTX)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Nutex Health Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 11 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 147.40 $ — 58% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
9 of 10 Growth gemTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 58.6% passed
- More than 10% revenue growth is expected for the coming year 10.3% passed
- Share count grows by less than 3% a year 16.9% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 110.4% passed
- Gross margin at 40% or higher and without meaningful erosion 50.8% passed
- Goodwill from acquisitions does not grow faster than revenue 1.5% passed
- Net debt below twice EBITDA 0.6 x EBITDA passed
- Operating cash flow covers the profits of the last three years 195 m passed
- Return on capital at 15% or higher, or up versus two years ago 36.2% passed
- Insiders hold at least 10% or are net buyers 29.1% passed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 67.2% above the current price.
- Consensus
- Strong Sell
- Analyst Ratings
- 3
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 21.52 | 15.20 – 24.37 | 880 | – | 5 |
| 12/31/2027 | 23.03 | 18.42 – 25.57 | 969 | 3.8% | 5 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- 5.26 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 12.10 | – | 258 | 269.80 | 23.90 | 0 | 0 |
| 2025: Q1 | 2.50 | – | 212 | 214.00 | 6.90 | 51 | 51 |
| 2025: Q2 | -2.68 | – | 244 | 220.70 | -7.30 | 27 | 27 |
| 2025: Q3 | 7.72 | – | 268 | 239.90 | 20.70 | 100 | 99 |
| 2025: Q4 | 1.65 | -86.40 | 152 | -41.10 | 7.80 | 70 | 69 |
| 2026: Q1 | 6.52 | 160.80 | 217 | 2.20 | 21.60 | 76 | 74 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | – | 0 | -7 | -3.60 | 0 | -6 | 1 |
| 2017 | 0 | -6 | 1 | 0.14 | -1 | 2 | 3 |
| 2018 | 0 | -2 | -3 | -0.39 | 0 | -2 | 0 |
| 2019 | 97 | 35 | 21 | 5.05 | 12 | 28 | 179 |
| 2020 | 274 | 153 | 106 | 24.69 | 81 | 86 | 309 |
| 2021 | 332 | 170 | 133 | 33.55 | 173 | 115 | 395 |
| 2022 | 219 | -407 | -425 | -100.36 | 51 | 96 | 432 |
| 2023 | 248 | -32 | -46 | -10.39 | 1 | 61 | 398 |
| 2024 | 480 | 131 | 52 | 10.23 | 23 | 146 | 655 |
| 2025 | 875 | 276 | 71 | 10.48 | 248 | 329 | 919 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Nutex Health Inc. ist ein Unternehmen für Gesundheitsdienstleistungen und -betrieb in den USA.
| Employees | 1,005 |
|---|---|
| Headquarters | Houston, TX |
| Address | 1776 Yorktown Street, 77056 Houston, United States |
| Phone | 713 660 0557 |
| Website | nutexhealth.com |
| IPO Date | 4. Apr 2022 |
| ISIN | US67079U1088 |
| Stock Split | 1:10 on 07/03/2024 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Thomas T. Vo M.B.A., M.D. | Chairman of the Board & CEO | 1973 |
| Warren Hosseinion M.D. | President & Director | 1972 |
| Jon C. Bates CPA, M.B.A. | Chief Financial Officer | 1971 |
| Wesley Bamburg FACHE | Chief Operating Officer | – |
| Michael Chang M.D. | Chief Medical Officer | 1972 |
| Jennifer Rodriguez | Investor & Public Relations Manager | – |
| LaTanya Brackens | Director of Compliance | – |
| Vivian Sanders M.B.A. | Director of Marketing | – |
| Sarah Wallace | Director of Human Resources | – |
| Elisa Michael Luqman Esq., J.D., M.B.A. | Chief Legal Officer & Board Secretary of SEC | 1964 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.